Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Platten

Showing results (191-200 of 318) with videos related to

Pageof 32
Sort By:
Cancers|January 13, 2021
A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human TumorsBarbara Costa, Michael N C Fletcher, Pavle Boskovic, et al.
Neurological Research and Practice|May 22, 2022
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomasLukas Bunse, Anne-Kathleen Rupp, Isabel Poschke, et al.
Neurology|September 27, 2013
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutationWolfgang Wick, Christoph Meisner, Bettina Hentschel, et al.
Scientific Reports|January 25, 2017
Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosisTobias V Lanz, Sarah K Williams, Aleksandar Stojic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2018
Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor TrametinibAnne Berberich, Tobias Kessler, Carina M Thomé, et al.
Acta Neuropathologica|September 16, 2023
Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosisAnnika Hofmann, Nik Krajnc, Assunta Dal-Bianco, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune diseasePeggy P Ho, Paulo Fontoura, Michael Platten, et al.
Oncotarget|February 17, 2015
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastomaTobias Kessler, Felix Sahm, Jonas Blaes, et al.
Neuro-Oncology Advances|October 5, 2022
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cellsKevin Hai-Ning Lu, Julius Michel, Michael Kilian, et al.
Neuro-Oncology Advances|July 10, 2020
Molecular profiling-based decision for targeted therapies in <i>IDH</i> wild-type glioblastomaTobias Kessler, Anne Berberich, Belen Casalini, et al.
Pageof 32

Showing results (191-200 of 318) with videos related to

Sort By:
Pageof 32
Cancers|January 13, 2021
A Set of Cell Lines Derived from a Genetic Murine Glioblastoma Model Recapitulates Molecular and Morphological Characteristics of Human TumorsBarbara Costa, Michael N C Fletcher, Pavle Boskovic, et al.
Neurological Research and Practice|May 22, 2022
AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomasLukas Bunse, Anne-Kathleen Rupp, Isabel Poschke, et al.
Neurology|September 27, 2013
Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutationWolfgang Wick, Christoph Meisner, Bettina Hentschel, et al.
Scientific Reports|January 25, 2017
Tryptophan-2,3-Dioxygenase (TDO) deficiency is associated with subclinical neuroprotection in a mouse model of multiple sclerosisTobias V Lanz, Sarah K Williams, Aleksandar Stojic, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 3, 2018
Targeting Resistance against the MDM2 Inhibitor RG7388 in Glioblastoma Cells by the MEK Inhibitor TrametinibAnne Berberich, Tobias Kessler, Carina M Thomé, et al.
Acta Neuropathologica|September 16, 2023
Myeloid cell iron uptake pathways and paramagnetic rim formation in multiple sclerosisAnnika Hofmann, Nik Krajnc, Assunta Dal-Bianco, et al.
Journal of Immunology (Baltimore, Md. : 1950)|October 21, 2005
A suppressive oligodeoxynucleotide enhances the efficacy of myelin cocktail/IL-4-tolerizing DNA vaccination and treats autoimmune diseasePeggy P Ho, Paulo Fontoura, Michael Platten, et al.
Oncotarget|February 17, 2015
Glioma cell VEGFR-2 confers resistance to chemotherapeutic and antiangiogenic treatments in PTEN-deficient glioblastomaTobias Kessler, Felix Sahm, Jonas Blaes, et al.
Neuro-Oncology Advances|October 5, 2022
T cell receptor dynamic and transcriptional determinants of T cell expansion in glioma-infiltrating T cellsKevin Hai-Ning Lu, Julius Michel, Michael Kilian, et al.
Neuro-Oncology Advances|July 10, 2020
Molecular profiling-based decision for targeted therapies in <i>IDH</i> wild-type glioblastomaTobias Kessler, Anne Berberich, Belen Casalini, et al.
Pageof 32